AI Article Synopsis
- The management of hepatitis B virus (HBV) infection during pregnancy in Japan is not well-established, prompting the study of five HBV-infected pregnant women treated with tenofovir disoproxil fumarate (TDF).
- Two of the cases involved women who were born after nationwide immunoprophylaxis against HBV, indicating a need to tackle mother-to-child transmission more effectively.
- TDF was found to safely suppress HBV replication in all mothers without serious side effects, resulting in healthy children free from congenital disorders and HBV infection, suggesting TDF's potential in preventing mother-to-child transmission.
Article Abstract
The appropriate management of hepatitis B virus (HBV) infection during pregnancy has not been established in Japan. We herein report five HBV-infected pregnant Japanese women who received tenofovir disoproxil fumarate (TDF). Two of them had been born after the introduction of nationwide immunoprophylaxis and were vertically infected with HBV, highlighting the need to address mother-to-child transmission further. In both entecavir-experienced and nucleoside/nucleotide analog-naïve mothers, TDF suppressed HBV replication without serious adverse events. All five children were free from congenital disorders, growth impairment, and HBV infection. TDF showed safety and efficacy for pregnant woman with chronic hepatitis B and might have helped prevent mother-to-child transmission.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008036 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.3504-19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!